Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Consensus Rating of “Hold” from Brokerages
by Michael Walen · The Markets DailyPharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Get Free Report) has received an average rating of “Hold” from the five research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $38.3333.
A number of analysts have recently weighed in on the company. Wall Street Zen raised Pharming Group to a “strong-buy” rating in a research report on Saturday, December 27th. Canaccord Genuity Group assumed coverage on Pharming Group in a research report on Friday. They issued a “buy” rating and a $37.00 price objective for the company. Oppenheimer reissued an “outperform” rating and issued a $41.00 price objective (down from $42.00) on shares of Pharming Group in a research report on Friday, March 13th. HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research note on Tuesday, March 24th. Finally, Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th.
Check Out Our Latest Research Report on Pharming Group
Pharming Group Stock Up 2.4%
Shares of Pharming Group stock traded up $0.41 during trading on Friday, reaching $17.39. The company’s stock had a trading volume of 782 shares, compared to its average volume of 27,501. The company has a quick ratio of 2.03, a current ratio of 2.59 and a debt-to-equity ratio of 0.33. The company has a market cap of $1.22 billion, a price-to-earnings ratio of 1,738.60 and a beta of 0.05. Pharming Group has a 1-year low of $7.79 and a 1-year high of $21.34. The company has a 50-day simple moving average of $16.23 and a two-hundred day simple moving average of $16.29.
Pharming Group (NASDAQ:PHAR – Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.08). The business had revenue of $106.50 million during the quarter, compared to analyst estimates of $111.76 million. Pharming Group had a return on equity of 1.08% and a net margin of 0.71%. As a group, equities analysts forecast that Pharming Group will post -0.2 earnings per share for the current year.
Hedge Funds Weigh In On Pharming Group
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC raised its stake in Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after acquiring an additional 28,615 shares during the last quarter. Millennium Management LLC purchased a new position in Pharming Group in the 4th quarter worth $360,000. SmartHarvest Portfolios LLC purchased a new position in Pharming Group in the 4th quarter worth $224,000. Finally, EverSource Wealth Advisors LLC purchased a new position in Pharming Group in the 2nd quarter worth $32,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.
About Pharming Group
Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.
The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.